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Ionizing radiation (IR) triggers programmed cell death in tumor cells through a variety
of highly regulated processes. Radiation-induced tumor cell death has been studied
extensively in vitro and is widely attributed to multiple distinct mechanisms, including
apoptosis, necrosis, mitotic catastrophe (MC), autophagy, and senescence, which may
occur concurrently. When considering tumor cell death in the context of an organism, an
emerging body of evidence suggests there is a reciprocal relationship in which radiation
stimulates the immune system, which in turn contributes to tumor cell kill. As a result,
traditional measurements of radiation-induced tumor cell death, in vitro, fail to represent
the extent of clinically observed responses, including reductions in loco-regional failure
rates and improvements in metastases free and overall survival. Hence, understanding
the immunological responses to the type of radiation-induced cell death is critical. In
this review, the mechanisms of radiation-induced tumor cell death are described, with
particular focus on immunogenic cell death (ICD). Strategies combining radiotherapy with
specific chemotherapies or immunotherapies capable of inducing a repertoire of cancer
specific immunogens might potentiate tumor control not only by enhancing cell kill but
also through the induction of a successful anti-tumor vaccination that improves patient
survival.
Keywords: ionizing radiation, immunogenic cell death, apoptosis, necrosis, autophagy, mitotic catastrophe,
senescence
INTRODUCTION
Radiation therapy (RT) is a well-established and effective form of
cancer treatment. Since radiotherapy effects within an irradiated
field are not tumor specific, the therapeutic ratio depends on the
ability to localize ionizing radiation (IR) delivery to the tumor site
and optimize dose and fractionation to preferentially kill tumor
cells better than exposed normal cells.
IR can directly damage the atomic structures of nucleic acids,
proteins, and lipids. In addition, molecular damage is indirectly
mediated by byproducts of radiation exposure, consisting of free
radicals produced from water radiolysis. Both the direct and indi-
rect effects of IR initiate a series of downstream signaling events
that result in either the repair of damaged macromolecules or
evolve toward some form of cell death. The detrimental effects
of radiation depend on both the dose and efficiency of damage
repair of the irradiated target. In tumor cells, the most biologi-
cally sensitive and clinically relevant macromolecule influencing
cell death is DNA, which is susceptible to single-strand breaks
(SSBs) and double-strand breaks (DSBs) (Giusti et al., 1998). It
is estimated that 1 Gy can produce 20–40 DSBs per cell, where
unrepaired DSBs can result in cellular lethality (Jonathan et al.,
1999; Schultz et al., 2000).
After radiation exposure, tumor cells undergo different types
of tumor cell death, including: apoptosis, necrosis, mitotic
catastrophe (MC), autophagy, and senescence (Gudkov and
Komarova, 2003; Eriksson and Stigbrand, 2010). The type of
cell death depends on several interrelated factors. These factors
include the cell type, radiation dose and quality, oxygen tension,
p53 mutation status, DNA repair capacity, redox state, and the
cell cycle phase at the time of IR exposure (Stewart et al., 2011).
In addition, different types of cell death pathways interact to
contribute to the final outcome within the irradiated tumor.
The classical pathways of IR-induced cell death well described
in vitro fail to adequately explain all in vivo experimental and
clinical observations. An abscopal (ab scopus, away from the tar-
get) response is perhaps the most convincing evidence that direct
DNA damage is not the only mechanism of tumor control. This is
supported clinically when radiation is delivered focally and tumor
response is systemic, for example when metastatic tumors outside
of the treated field respond to treatment (Nobler, 1969; Ehlers and
Fridman, 1973; Ohba et al., 1998; Takaya et al., 2007).
Evidence in experimental models suggests that radiation-
induced promotion of anti-tumor immune responses can explain
these abscopal effects (Chakravarty et al., 1999; Demaria et al.,
2004; Shiraishi et al., 2008; Dewan et al., 2009). However, a
gap exists in bridging the current understanding of principles
in radiation biology and this effect of IR on immune activation.
Immunogenic cell death (ICD) has become a topic of discussion
to both explain initiating events and optimize the clinical ben-
efit of the abscopal effect. This review will focus on the modes
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of tumor cell death following IR, the methods used to interro-
gate cell death modalities, and the consequences of cell death on
tumor-host interactions. Additional effects of RT on the tumor
microenvironment have been reviewed elsewhere (Gudkov and
Komarova, 2003; Barcellos-Hoff et al., 2005).
APOPTOSIS
Apoptosis is a highly regulated mechanism of programmed cell
death that plays a fundamental role in embryonic development
and tissue homeostasis to eliminate unwanted, damaged, or
abnormal cells. Cells undergoing apoptosis are characterized by
distinct cytoplasmic and nuclear morphologic changes, including
membrane blebbing, DNA fragmentation and nuclear conden-
sation. Dysregulation of apoptosis, however, is associated with
unchecked cell proliferation and is thought to be essential for the
development and progression of cancer (Fuchs and Steller, 2011).
Thus, therapies that augment apoptosis have become a powerful
tool in treating cancer.
The apoptotic pathway comprises a complex network of
proteins that are cell type and spatiotemporally dependent.
Genes involved in apoptosis may act in concert or show redun-
dancy (Kuribayashi et al., 2011). Nonetheless, distinct apop-
totic pathways have been clearly defined in IR exposed tumor
cells.
Depending on dose and cell type, RT may cause apoptosis via
the membrane stress pathway (ceramide production and subse-
quent second messenger signaling), the intrinsic pathway (mito-
chondrial release of cytochrome and subsequent apoptosome
formation), and the extrinsic pathway (death receptor mediated
caspase activation) (Figure 1) (Cain et al., 1999; Ogura et al.,
2009). IR primarily acts through the intrinsic pathway, but it has
also been shown to involve certain aspects of the membrane stress
and extrinsic pathways (Takasawa et al., 2005).
IR-induced apoptosis through the intrinsic apoptotic pathway
is mediated by DNA SSBs and DSBs (Gudkov and Komarova,
2003). This damage elicits subsequent downstream signaling to
either block cell cycle progression, allowing for DNA repair, or
progression to cell death when DNA damage is overwhelming.
ATM and ATR activation mediate the early responses to IR that
regulate cell cycle progression and DNA repair (Maltzman and
Czyzyk, 1984). In the presence of DSBs, Mre11/Rad50/Nbs1 com-
plexes form at DSB sites and recruit ATM to sites of repair. ATM
undergoes autophosphorylation and phosphorylates checkpoint
protein kinase 2 (Chk2) (Smith et al., 2010; Rodriguez-Rocha
et al., 2011). At SSB sites, Rad1/Rad9/Hus1 and Rad17/RFC
complexes form and recruit ATR. ATR undergoes autophospho-
rylation, and soon after phosphorylates checkpoint protein kinase
1 (Chk1) (Smith et al., 2010; Rodriguez-Rocha et al., 2011).
Activated Chk1 and Chk2 block tumor cell cycle progression by
regulating DNA repair and cell cycle proteins, including BRCA1,
MDM2, and p53 (Cortez et al., 1999; Kim et al., 2002; Lukas et al.,
2004; Shi et al., 2004).
The accumulation of p53 is critical to IR-induced apopto-
sis. Activated ATM phosphorylates nuclear p53 protein on serine
15, thereby preventing its ubiquitination by MDM2 and subse-
quent proteasomal degradation (Siliciano et al., 1997; Dumaz and
Meek, 1999; Tichy et al., 2009). Additionally, ATM/ATR-activated
Chk1 and Chk2 kinases phosphorylate the p53 transactivation
domain on serine 20, thereby stimulating p53 activity (Dornan
et al., 2003). These p53 phosphorylation events result in the
nuclear accumulation of transcriptionally active p53, which in
turn transactivates the pro-apoptotic genes PUMA, Bax, and
Noxa (Oda et al., 2000; Dogu and Diaz, 2009; Kuribayashi et al.,
2011).
A fine balance regulates this pathway. In the cytoplasm, p53 is
associated with the anti-apoptotic protein Bcl-XL. When PUMA
is translocated into the cytoplasm it disrupts the Bcl-XL/p53
complex and liberates p53 (Chipuk et al., 2005). Free cyto-
plasmic p53 disrupts the Bcl2/Bax complex by associating with
the anti-apoptotic protein Bcl2 and releasing the pro-apoptotic
protein Bax.
Bax induces permeabilization of the outer mitochondrial
membrane to trigger cell death through the release of cytochrome
c from the mitochondria (Marzo et al., 1998; Dejean et al., 2006;
Dogu and Diaz, 2009). In the cytoplasm, cytochrome c, Apaf-1,
and ATP form the apoptosome and activate caspase-9, thereby
initiating the postmitochondrial-mediated caspase cascade by
activating effector caspases 3 and 7 (Cain et al., 1999).
In addition to the intrinsic apoptotic pathway, IR is also
involved in the canonical extrinsic apoptotic pathway. The classic
apoptotic machinery of the extrinsic pathway involves signal-
ing through death receptors (DRs), which belong to the tumor
necrosis factor (TNF) receptor superfamily.
IR activation of p53, results in downstream transactivation
of CD95/Fas, KILLER/DR5, and the CD95/Fas ligand (CD178)
(Sheard, 2001; Harms et al., 2004). CD95/Fas ligand bind-
ing to CD95/Fas induces trimerization and clustering of the
intracellular death domain (DD) region of the receptor. The
DD recruits the adaptor protein, Fas-associated death domain
(FADD) (Sheard, 2001). The death effector domain (DED) of
FADD recruits pro-caspase-8, forming the death-inducing signal-
ing complex (DISC). Activation of the initiator caspase-8 leads
to activation of effector caspases 3 and 7, which act to disassem-
ble cellular structures. Interestingly, IR associated up-regulation
of CD95/Fas on tumor cells improves tumor cell kill by effector
CD8+ cytotoxic T lymphocytes (CTLs) that express CD95/Fas lig-
and and may also play a role in delayed apoptosis associated MC
(Luce et al., 2009).
Strategies aimed at augmenting apoptosis constitute a com-
mon research area in oncology. However, p53 is mutated in
∼50% of cancers and the apoptotic machinery is defective in
most others, influencing responses to IR. In fact, tumors that are
susceptible to p53 dependent apoptosis are quite radiosensitive,
whereas, tumors that overexpress antiapoptotic proteins (BCL2,
Bcl-XL, and Survivin) or lose expression of proteins involved in
the apoptotic machinery are radioresistant (Cuddihy and Bristow,
2004; Rodel et al., 2005).
In cancers with p53 mutations, unchecked cell proliferation
occurs in spite of DNA damage by IR. When this happens, the
tumor cells accumulate DNA mutations, become aneuploid, and
develop micronuclei, leading to MC and subsequent cell death
(Lane, 1992). Interestingly, MC is frequently followed by delayed
apoptosis in apoptosis-competent cells (Gudkov and Komarova,
2003). Since p53 mutation is frequently seen in tumor cells,
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FIGURE 1 | Apoptosis and necrosis. IR-induced apoptosis through the
intrinsic apoptotic pathway begins with the development of DNA DSBs.
ATM and CHK2 associated p53 phosphorylation events result in the nuclear
accumulation of transcriptionally active p53, which in turn transactivates the
pro-apoptotic genes PUMA, Bax, and Noxa. Cytoplasmic PUMA disrupts the
Bcl-XL/p53 complex and liberates p53. Free cytoplasmic p53 disrupts the
Bcl2/Bax complex by associating with the anti-apoptotic protein Bcl2 and
releasing the pro-apoptotic protein Bax. Bax triggers cell death through the
release of cytochrome c from the mitochondria, resulting in apoptosome
formation and activation effector caspases and apoptosis. The extrinsic
pathway involves signaling through death receptors. IR activation of p53,
results in downstream transactivation of CD95/Fas and the CD95/Fas ligand.
CD95/Fas ligand binding to CD95/Fas induces trimerization and clustering of
the intracellular death domain (DD) region of the receptor. The DD recruits
the adaptor protein, Fas-associated death domain (FADD). The death effector
domain of FADD recruits pro-caspase-8, forming the death-inducing signaling
complex. Activation of the initiator caspase-8 leads to activation of effector
caspases and apoptosis. Additionally, IR-induced membrane stress leads to
ceramide production, second messenger signaling, and apoptosis. RIP1
protein is associated with the FADD and is a key upstream kinase involved in
the activation of regulated necrosis. Regulated necrosis is sustained in death
receptor stimulated cells that are caspase-8 deficient or inhibited.
MC may be the predominant form of cell death following IR
exposure to tumor cells, even though this effect is cell-type
dependent.
NECROSIS
Necrosis is a tumor cell death pathway that predominates in
response to very large doses of radiation. At lower doses it
is often viewed as an accidental, unregulated event. In con-
trast to apoptosis, necrosis does not display signs of ordered
DNA fragmentation. Necrotic morphology is evident in studies
using light or electron microscopy. Cells display the morpho-
logical features of organelle swelling, mitochondrial dysfunc-
tion, and plasma membrane permeabilization with subsequent
loss of intracellular contents, including immune stimulating
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“danger signals” (Galluzzi and Kroemer, 2008; Hotchkiss et al.,
2009).
IR-induced necrosis in tumor cells is not to be confused with
the indirect effects of IR occurring as untoward toxic effects in the
clinic, like delayed osteoradionecrosis or central nervous system
(CNS) radiation necrosis after high dose IR exposure of nor-
mal bone or brain tissue, respectively (Chrcanovic et al., 2010;
Fink et al., 2012; Siu et al., 2012). These indirect effects of IR are
mediated by vascular dysfunction, thereby making normal cells
susceptible to undergoing necrosis due to hypoxia and nutrient
depletion (Garcia-Barros et al., 2003; Teng and Futran, 2005;
Ruegg et al., 2011).
Recent literature suggests that IR can directly induce regulated
tumor cell necrosis (Nehs et al., 2011). Programmed necrosis
(necroptosis) displays some overlap with apoptosis. It is a cel-
lular mechanism of necrotic cell death induced by apoptotic
stimuli, i.e., ligand-DR engagement, under conditions where the
apoptotic machinery is either deficient or blocked (Figure 2)
FIGURE 2 | Mitotic catastrophe and senescence. Mitotic catastrophe (MC)
occurs after failed mitosis. Cells are characterized by an increased frequency
of multiple nuclei and micronuclei. Checkpoint control is greatly reduced in
mutant p53 tumor cells, making the cells susceptible to premature mitosis,
chromosomal dysegregation, the generation of aneuploid progeny, and MC
associated cell death. Senescence on the other hand, is a form of irreversible
growth arrest that halts the proliferation of metabolically active cells.
IR-induced accelerated senescence in tumor cells is centered around p53.
When IR induced DSBs result in p53 activation, activated p53 promotes the
activity of p21, an inhibitor of CDK/cyclin complexes and cell cycle
progression. Senescent cells display the loss of replicative potential, cell
cycle arrest, and enlarged and flattened morphology.
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(Degterev et al., 2008). Both apoptosis and necrosis share compo-
nents of the DR signaling apparatus, specifically at the level of the
FADD (Stanger et al., 1995; Vanden Berghe et al., 2004). In both
forms of cell death, the deciding factor of whether a cell commits
apoptosis or necrosis depends on the FADD associated activities
of caspase-8 and receptor interacting protein 1 (RIP1) (Lin et al.,
1999; Holler et al., 2000).
RIP1 is a key upstream kinase involved in the activation of
necroptosis (Degterev et al., 2008). It interacts with the DD of
FADD and is regulated by its ubiquitination and cleavage states
(Vanden Berghe et al., 2004; Declercq et al., 2009). When RIP1
is polyubiquitinated it functions as a pro-survival scaffold and
promotes downstream activation of mitogen-activated protein
kinases (MAPKs) and NFκ-B, which both govern the expression
of pro-survival genes (Declercq et al., 2009). However, upon RIP1
polyubiquitin chain removal, RIP1 associated MAPK and NFκ-B
activation is abolished, and RIP1 downstream necroptotic sig-
naling is preferentially promoted through the mitochondrial per-
meability transition complex, as opposed to mitochondrial outer
membrane permeabilization transition complex, seen in apopto-
sis (Declercq et al., 2009). This effect is sustained inDR stimulated
cells that are caspase-8 deficient or inhibited (blocked by pan-
caspase inhibitors, i.e., zVAD-fmk). Nevertheless, if caspase-8 is
intact and active, it can cleave RIP1, thereby turning off necrop-
tosis, and alter the balance of cell death in favor of apoptosis
(Lin et al., 1999).
Recent work by Nehs et al. demonstrated that necroptosis
contributed to IR-induced cell death of anaplastic thyroid and
adrenocortical cancers (Nehs et al., 2011). They showed that
IR-induced cell death could be abrogated with necrostatin-1, a
small molecular inhibitor of RIP1, in RIP1 expressing tumor cells
(Degterev et al., 2008; Nehs et al., 2011). They proposed that
necroptosis augmentation, involving an activator of RIP1 kinase
or its downstream effectors, might radiosensitize cells. However,
further studies are required to clarify the role of necroptosis in
IR-induced cell death and the subsequent spillage of immune
stimulating “danger signals” (Nehs et al., 2011).
MITOTIC CATASTROPHE
MC occurs after failed mitosis. Cells are characterized by an
increased frequency of multiple nuclei and micronuclei. MC acts
as an oncosuppresive mechanism for the avoidance of genomic
instability (Vitale et al., 2011). Tumor cells that undergo MC
often have checkpoint deficiencies that result in incomplete DNA
repair, replicative infidelity, and chromosomal dysegregation
(Eriksson and Stigbrand, 2010). Thus, loss of checkpoint control
in IR exposed tumor cells eventually leads to the generation of
aneuploid progeny and MC associated cell death (Ianzini et al.,
2006).
Mutant p53 tumor cells are susceptible to IR-induced MC
(Ianzini et al., 2006; Eriksson and Stigbrand, 2010). Normally,
p53 acts as a post-transcriptional negative regulator of cyclin
B1 protein (a cell cycle regulated protein that abrogates the
G2/M checkpoint) levels and centrosome amplification. However,
in p53 mutant cells, cyclin B1 levels are elevated and centro-
some frequency is amplified (Eriksson and Stigbrand, 2010).
This contributes to both premature mitosis and chromosomal
dysegregation, leading to MC. Not surprisingly, inhibition of
other G2 checkpoint proteins (ATM, ATR, Chk1, Chk2, and p21)
promotes DNA damage, aneuploidy, and MC (Castedo et al.,
2004; Hirose et al., 2005; Vogel et al., 2007).
Interestingly, MC is associated with delayed apoptosis in irra-
diated tumor cells. An increase in CD95/Fas, TRAIL-R, and
TNF-R expression and sensitization to early apoptosis heralds a
delayed increase in FasL, TRAIL, and TNFα expression and results
in the execution of delayed apoptosis linked to MC (Luce et al.,
2009). Not only are the ligands expressed on the surface of tumor
cells, but they are also produced in the soluble form, resulting in
death of ligand sensitive bystander tumor cells (Luce et al., 2009).
Recently, caspase-2 has been identified as an initiator caspase
following DNA damage and is activated during apoptosis follow-
ing MC (Vitale et al., 2011). However, some researchers believe
that caspase-2, at best, is an amplifier of the apoptotic cascade
and may not be relevant to apoptosis at all (Krumschnabel et al.,
2009). Moreover, some evidence suggests that that MC may pro-
mote necrosis (rather than apoptosis) (Vakifahmetoglu et al.,
2008). Since the concept of regulated necrosis is gaining consen-
sus, attempts at understanding its relationship to IR-induced MC
may prove important.
SENESCENCE
Senescence is a form of irreversible growth arrest that halts the
proliferation of metabolically active ageing and damaged cells.
Similar to other forms of cell death, it is a process that prevents
the transmission of damaged genetic material to daughter cells.
Several key features distinguish senescent cells, including the loss
of replicative potential, cell cycle arrest, enlarged and flattened
morphology, and expression of senescence-associated markers
(for example senescence-associated β-galactosidase, SA-β-gal)
(Suzuki et al., 2001). IR has been reported to promote accel-
erated senescence in normal and cancer cells (Mendonca et al.,
2011). Indeed, the progeny of irradiated cells accumulate struc-
tural chromosomal aberrations in a dose dependent fashion,
which precedes senescence (Zahnreich et al., 2010). Similar to
other forms of cell death, p53 plays a central role in IR-induced
accelerated senescence in tumor cells (Jones et al., 2005; Quick
and Gewirtz, 2006; Lehmann et al., 2007).
Senescence is an option exercised in normal epithelial cells
during aging, where the process is well described. In brief,
p53 activation promotes activity of p21, which acts to block
CDK/cyclin complexes and cause G1 cell cycle arrest. This effect
is paralleled by p53 suppression of cyclin B1 expression during
IR-induced G2 cell cycle arrest. Subsequent to p21 induction,
p16 expression is induced, while p21 levels decline. It is recog-
nized that p21 is involved in the initial induction of G1 arrest
and p16 is required for its extended maintenance, whereby p16
prevents CDK4 and CDK6 from phosphorylating Rb protein,
which binds E2F and prevents transcription of genes required
for cell cycle progression. As expected, inactivation of DNA dam-
age checkpoint kinases prevents senescence and restores cell cycle
progression (Fagagna et al., 2003).
The telomere also plays a crucial role in IR-induced senes-
cence of cancer cells (Crompton, 1997). Telomeres consist of
short, highly repetitive DNA sequences located at the ends of
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chromosomes. Telomere length is maintained by telomerase
(a complex consisting of a reverse transcriptase and RNA tem-
plate). In tumor cells, IR produces chromosome end associated
abnormalities, including end-to-end fusions (an indicator of
telomere dysfunction) (Jones et al., 2005). Telomere dysfunction,
rather than changes in telomerase activity or telomere length,
induces senescence in a p53 dependent manner (Jones et al.,
2005). In contrast, p53 mutant cells are unable to arrest and
succumb to other forms of cell death, including apoptosis, necro-
sis, autophagy, and MC (Jones et al., 2005; Lehmann et al.,
2007). Interestingly, nutlin-3, a small molecular p53 activator, was
shown to be an effective radiosensitizer, and its effect was entirely
attributable to an increased induction of p53 dependent cellular
senescence in prostate cancer cells (Lehmann et al., 2007).
Senescent cells have a distinct secretory repertoire called senes-
cence associated secretory phenotype or SASP (Coppe et al.,
2010). Recent studies in liver cancer and sarcoma mouse models
suggest that reactivation of p53 in p53-deficient tumors in vivo
produces complete tumor regression predominately due to senes-
cence induction (Ventura et al., 2007; Xue et al., 2007). These
studies demonstrate that cellular senescence can limit tumor
growth and may contribute to improved long-term survival. In
fact, SASP mediated inflammatory cytokines may activate the
innate immune system as a mediator of tumor regression (Xue
et al., 2007). Again, the relationship between IR-induced senes-
cence and an immune host response to tumor cells has not been
established.
AUTOPHAGY
Autophagy is characterized by the segregation of damaged or
unwanted ER and cytoplasmic constituents into autophagosomes,
destined for lysosomal degradation. It is paradoxical as it is
actually a survival mechanism that induces a particular type
of death when overstimulated. Autophagy is noted for its role
in maintaining metabolic homeostasis in tumor cells undergo-
ing chronic hypoxia and nutrient depletion (Bursch et al., 2008;
Munz, 2009; Orvedahl and Levine, 2009). Yet, its effects are two-
fold (Tsuchihara et al., 2009; Palumbo and Comincini, 2012; Wu
et al., 2012). Low to moderate levels of autophagy enhance cell
growth and repair by altering the cellular composition and gen-
erating building blocks available for the biosynthesis of complex
molecules. Next to the proteasome, autophagy is an impor-
tant catabolic pathway necessary for recycling amino acid, fatty
acid, and energy (in the form of ATP) (Munz, 2009; Rodriguez-
Rocha et al., 2011). In contrast, hyper-activation of autophagy
promotes cell death, when degradation of cytoplasmic contents
proceeds to completion (Huang and Klionsky, 2007; Chen and
Karantza-Wadsworth, 2009).
While IR has been shown to induce autophagy in tumor
cells, the literature is conflicting, regarding whether IR-induced
autophagy promotes cell survival or cell death (Paglin et al., 2001;
Yao et al., 2003; Ito et al., 2005; Chaachouay et al., 2011; Kim et al.,
2011; Wu et al., 2012). Several studies demonstrate that blocking
autophagy radiosensitizes, while promoting autophagy radiopro-
tects. The authors argue that IR-induced autophagy is an adaptive
response to sustain tumor growth and survival (Chaachouay
et al., 2011; Kim et al., 2011). Conversely, other reports show
that augmenting IR-induced autophagy increases cell death of
radioresistant tumor cells, particularly when an overwhelming
amount of autophagy is achieved (Fujiwara et al., 2007; Gewirtz,
2007; Gewirtz et al., 2009; Kuwahara et al., 2011). Undoubtedly,
autophagy is a complex response and understanding its role in RT
is evolving.
Specifically, the upstreammolecularmachinery involved in IR-
induced autophagy remains unclear (Li et al., 2012). Although
IR is known to damage proteins and lipids, IR-induced DNA
damage is believed to be the initiating event responsible for
autophagy. Recent reports indicate that p53 and PARP-1, a DNA
repair enzyme activated by DNA damage, play important roles in
autophagy initiation. Both proteins act to inhibit mTOR activity
and regulate mTOR’s downstream targets, including autophagy
(Feng et al., 2005; Huang and Shen, 2009; Rodriguez-Rocha et al.,
2011). Interestingly, PARP-1 activation has also been implicated
in the necrotic pathway, whereas its caspase-dependent cleavage
and inactivation is a downstream event of apoptosis (Huang and
Shen, 2009).
Upon initiation of autophagy, the phagophore (a nidus for
membrane production) is generated either de novo or from pre-
existing ER membranes (Bernales et al., 2007; Li et al., 2008).
A class III PI3K complex (Beclin, Class III PI3K, and p150)
recruits LC3 and ATG proteins (ATG12-ATG-5-ATG16L com-
plexes) to the membrane and facilitates membrane expansion.
Complete sequestration by the elongating phagophore results in
autophagosome formation. After formation, the autophagosome
fuses with the lysosome to become an autophagolysosome, where
lysosomal hydrolases digest the sequestered cytoplasmic derived
contents (Figure 3) (Li et al., 2008, 2012).
Several key proteins regulate autophagy. The canonical class
I PI3K/PKB/AKT/mTOR signaling pathway promotes protein
synthesis and acts as a negative regulator of autophagy. The bind-
ing of insulin/IGF-1 to the insulin receptor has been shown to
activate PI3K. Activated PI3K converts Ptdlns(4,5)P2 to yield
Ptdlns(3,4,5)P3 at the plasma membrane, leading to PKB/AKT
activation. Activated PKB/AKT further activates mTOR (an
autophagy inhibitor) through inhibiting the TSC1/TSC2 com-
plex, a repressor of the mTOR activating protein Rheb (Li et al.,
2008, 2012; Vellai and Takacs-Vellai, 2010).
Autophagy can be manipulated at several nodes along its path-
way. It can be blocked with chloroquine (a lysosomal enzyme
inhibitor that reduces autophagosome clearance), Bafilomycin A
(a lysosomal proton pump inhibitor that reduces lysosomal
acidification and autophagy clearance), 3-MA (a class III PI3K
inhibitor), and small interfering RNA to the autophagic machin-
ery (Beclin and the ATG proteins) (Ito et al., 2005; Chen
et al., 2011). Conversely, autophagy can be activated with AKT
inhibitors and rapamycin, a small molecular inhibitor to mTOR
(Fujiwara et al., 2007).
Recent evidence shows that blocking the autophagic machin-
ery with small interfering RNA prevents the release of the immune
stimulating “danger signal”, ATP, in chemotherapy treated tumor
cells undergoing ICD (Michaud et al., 2011). However, the con-
nection between irradiated tumor cells and their release of ATP as
part of an immune stimulating process is currently being defined
(Ohshima et al., 2010; Zappasodi et al., 2010).
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FIGURE 3 | Autophagy. The MAPK/erk 1/2 and PI3K-I/AKT signaling
pathways block the promotion of autophagy via the activation of MTOR.
IR-induced DNA damage activates p53, which acts as a negative regulator of
MTOR. Upon initiation of autophagy, the phagophore is generated. A class III
PI3K complex (Beclin, class III PI3K, and p150) recruits LC3 to the membrane
and facilitates membrane expansion. Complete sequestration by the
elongating phagophore results in autophagosome formation. After
formation, the autophagosome fuses with the lysosome to become an
autophagolysosome, where lysosomal hydrolases digest the sequestered
cytoplasmic derived contents.
IMMUNOGENIC CELL DEATH
Three distinct arms orchestrate ICD in dying tumor cells and
are required for immune priming and activation: (1) the cell
surface translocation of calreticulin (CRT, an ER residing pro-
tein chaperone and potent DC “eat me” signal), and the extra-
cellular release of (2) HMGB1 (a DNA binding protein and
TLR-4 mediated DC activator) and (3) ATP (an activator of
the DC P2X7 purinergic receptor that triggers DC inflam-
masome activation, secretion of IL-1β, and subsequent prim-
ing of IFNγ producing CD8+ T cells) (Figure 4) (Ma et al.,
2010). Whereby, the net effects of all three arms act to pro-
mote DC phagocytosis of tumor cells, processing of tumor-
derived antigens, and DC-associated cross-priming of CD8 +
CTLs. However, to date a direct causal link between radiation-
induced ICD and an abscopal effect involving the immune system
has not been established (Demaria et al., 2004; Dewan et al.,
2009). Thus, the challenge remains in understanding the role
of radiation-induced ICD and whether or not manipulation of
this subroutine of cell death has any significant clinical implica-
tions.
CRT cell surface exposure, as described by Kroemer and
Zitvogel, is a DC “eat me” signal that involves the coordi-
nated activation of three specific modules: ER stress, apoptosis,
and CRT/ERp57 translocation (Panaretakis et al., 2009). The
ER stress module requires eIF2 phosphorylation (a marker for
ER stress and translation inhibition). The apoptotic module
requires caspase-8 activation, Bap31 cleavage, and Bax/Bak acti-
vation. Lastly, the translocation module requires anterograde
ER-Golgi trafficking and extracellular exposure of CRT/ERp57.
Recent studies show that cell surface CRT translocation occurs
in IR exposed tumor cells (Obeid et al., 2007; Perez et al.,
2009).
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FIGURE 4 | Immunogenic cell death. Three distinct arms orchestrate ICD in
dying tumor cells and are required for immune priming and activation: (1) the
cell surface translocation of calreticulin (CRT) and the extracellular release of
(2) HMGB1 and (3) ATP. CRT cell surface exposure acts as a dendritic cell
“eat me signal” and involves the coordinated activation of 3 specific
modules: ER stress, apoptosis, and ER-Golgi trafficking and extracellular
exposure of CRT. HMGB1 is passively released from dying tumor cells and
acts as a cytokine and danger associated molecular pattern protein that
mediates responses to infection, injury, and inflammation. ATP is released
from dying tumor cells and involves the autophagic machinery. Extracellular
ATP activates the dendritic cell (DC) P2X7 receptor, which is involved in the
upregulation and activation of the DC inflammasome.
In contrast to CRT, cell surface CD47 (a DC “don’t eat me”
signal) is widely expressed in solid and hematogenous tumor cells
(Willingham et al., 2012). CD47 was discovered on newly formed
circulating red blood cells (RBCs) and shown to prevent RBC
clearance by the splenic reticuloendothelial system (Khandelwal
et al., 2007). CD47 blockade of tumor cells and normal tissues is,
respectively, associated with immune mediated tumor rejection
and radioprotection (Maxhimer et al., 2009; Willingham et al.,
2012). However, the role of CD47 in response to IR in tumor cells
is yet to be determined.
HMGB1 is an evolutionary conserved nuclear protein that
is expressed by almost all cells (cells with an intact nucleus)
and is important for the regulation of transcription (Lotze and
Tracey, 2005).When released from dying cells, it acts as a cytokine
and danger associated molecular pattern (DAMP) protein that
mediates responses to infection, injury, and inflammation; thus
HMGB1 has been called by Lotze and Tracey the immune system’s
“nuclear weapon” (Lotze and Tracey, 2005). HMGB1 released
from tumor cells binds to TLR4 on DCs, thus contributing to DC
activation (Apetoh et al., 2007).
HMGB1 is released into the extracellular space from cells in
one of two ways: either actively or passively. Active release involves
HMGB1 hyperacetylation in the nucleus followed by vesicular
secretion into the immunological synapse or into the extracellular
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space. HMGB1 is actively secreted by activated macrophages,
mature DCs, and activated NK cells (Lotze and Tracey, 2005).
In contrast, tumor cells passively release HMGB1 when they
undergo either sustained autophagy, late apoptosis, or necro-
sis (Lotze and Tracey, 2005). Passively released HMGB1 signals
through RAGE, TLR2, and TLR4, where it promotes the tran-
scription of pro-inflammatory genes in immune cells.
In addition to promoting an inflammatory response in
immune cells, extracellular HMGB1 can trigger autophagy or
apoptosis in bystander cancer cells, depending on its redox state.
Reduced HMGB1 binds to RAGE, induces Beclin dependent
autophagy and promotes resistance to IR and chemotherapy in
pancreatic and colon cancer cells (Tang et al., 2010). In contrast,
oxidized HMGB1 increases the cytotoxicity of these agents and
induces apoptosis via the mitochondrial pathway (Tang et al.,
2010). Currently, the redox state of HMGB1 released from IR
exposed tumor cells has not been determined.
ATP release is yet another important ICD component. It
involves the autophagic machinery, where knock down of ATG7
and ATG5 blocks ATP release (Michaud et al., 2011). Recently,
IR has been shown in several models to cause the release of
ATP from dying tumor cells and activation of immune cells via
the P2X7 purinergic receptor pathway (Ohshima et al., 2010;
Zappasodi et al., 2010). This pathway involves the ATP-P2X7
receptor stimulation followed by upregulation and activation of
the DC inflammasome (a large multiprotein complex composed
of NLRP3, Cardinal, the adaptor ASC, and pro-caspase-1). DC
inflammasome activation results in the synthesis and secretion
of IL-1β, where secreted IL-1β initiates further pro-inflammatory
events (Petrovski et al., 2011).
ABSCOPAL RADIATION RESPONSES
RT is employed as a local treatment modality with the intent to
kill tumor cells and reduce local recurrence. Considerable evi-
dence demonstrates that RT effects extend beyond the treatment
field (Formenti and Demaria, 2009). As mentioned earlier, the
abscopal effect is a term used to describe tumor regression in
lesions outside of the treatment field when one tumor site is
irradiated. Known for almost 60 years as a rare unexplained phe-
nomenon in patients receiving local RT (Mole, 1953), it could be
the result of RT-induced ICD that generates an in situ vaccine (Ma
et al., 2010). In support of this notion, interventions that pro-
mote the functionality of DCs or improve T cell activation induce
the abscopal effect in an unfavorable tumor microenvironment,
where the effect is otherwise unseen (Chakravarty et al., 1999;
Demaria et al., 2004, 2005). This strongly suggests that, while RT
may be efficient at releasing tumor antigens, the immunosuppres-
sive tumor microenvironment may hamper the development of
therapeutically effective anti-tumor immune responses.
Additional evidence supports the hypothesis that local RT
induces immune-mediated systemic anti-tumor effects. For
instance, the well documented association between optimal local
control and survival in several breast cancer trials, at a time
when occult systemic disease is often already present implies
the induction of a systemic anti-tumor mechanism by local RT.
In fact, two meta-analyses of prospective randomized trials on
the effects of local radiotherapy for breast cancer determined
that a 20% absolute reduction in 5-year local recurrence led
to a 5% absolute reduction in 15-year breast cancer mortality
(a four-to-one ratio of absolute effects) (Clarke et al., 2005; Darby
et al., 2011).
Since some chemotherapy drugs can also induce ICD (e.g.,
Mitoxantrone, Adriamycin, and Oxaliplatin) (Garg et al., 2010;
Zitvogel et al., 2010; Kepp et al., 2011; Kroemer et al., 2011),
it is intriguing to consider if the superiority of concomitant
versus sequential chemo-radiation is due to a synergistic induc-
tion of ICD (Glynne-Jones and Hoskin, 2007; Formenti and
Demaria, 2008). Chemotherapy-induced ICD was found to be
a non-mutually exclusive subroutine of tumor cell death that
includes components of the apoptotic, autophagic, and necrotic
machineries (Garg et al., 2010; Zitvogel et al., 2010; Kepp et al.,
2011; Kroemer et al., 2011). Prior to dying, tumor cells exposed
to ICD-inducing drugs were shown to release pro-inflammatory
cytokines and alter their display of cell surface antigens, thereby
becoming less tolerogenic and more immunogenic (Green et al.,
2009). These dying tumor cells were able to prime the immune
system of mice and prevent tumor reestablishment when the
immunized mice were subsequently re-challenged (Tesniere et al.,
2010; Michaud et al., 2011).
Interestingly, patients with breast cancer who are treated
with chemotherapy and radiotherapy and carry a TLR4 loss-of-
function allele relapse faster than those carrying the normal TLR4
allele (Apetoh et al., 2007). Thus, HMGB1-TLR4 DC signaling is
a clinically relevant immunoadjuvant pathway triggered by tumor
cell death (Apetoh et al., 2007).
FUTURE DIRECTIONS
Whether RT specifically and efficiently elicits ICD remains a criti-
cal research question. Most of the work of ICD has been described
with the use of chemotherapeutic compounds. However, emerg-
ing clinical evidence has renewed interest in studying the mecha-
nisms of IR-induced ICD.
Several reports have shown that IR and chemotherapeu-
tic agents induce “danger signals” that may contribute to an
immune-mediated response at the tumor site, thereby reverting
the immunosuppressive microenvironment of established tumors
(Ma et al., 2010). IR and chemotherapeutic agents act to pro-
mote an anti-tumor immune response in the tumor microen-
vironment via ICD pathways, triggering the cross-presentation
of tumor-derived antigens by DCs (Ma et al., 2010). However,
in the clinical setting each treatment alone may not quantita-
tively and/or qualitatively achieve tumor cell death in the manner
that triggers immune-mediated tumor rejection. Thus, further
studies are needed to determine the optimal IR and chemother-
apeutic treatments that reposition each other to optimally
elicit ICD.
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